Roche Licenses Halozyme’s ENHANZE Technology for ~$190M for the Development of Therapeutic Targets

 Roche Licenses Halozyme’s ENHANZE Technology for ~$190M for the Development of Therapeutic Targets

Roche Licenses Halozyme’s ENHANZE Technology for ~$190M for the Development of Therapeutic Targets

 Shots:

  • Halozyme to receive $25M upfront plus $160 to $165M/target milestones payments based on development, regulatory & sales in addition to royalties. Roche to get rights for ENHANZE Technology for exclusive development of clinical stage candidates for therapy areas
  • Roche also has an option to add two additional targets within a span of four years, in response Halozyme will receive a nomination fee for added targets. The initiation of the transaction is expected in Q4’19
  • Halozyme’s ENHANZE drug discovery technology is based on recombinant human hyaluronidase enzyme (rHuPH20) with SC delivery system. In 2006, Roche & Halozyme signed an agreement for ENHANZE and developed Rituxan, Rituxan Hycela & Herceptin

 Click here to read full press release/ article | Ref: Halozyme | Image: Business Wire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post